Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech

<< Previous

Bullboard Posts

Next >>

Comment by laroplexon Aug 21, 2024 9:50am

112 Views

Post# 36189574

RE:H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech

Total disconnect from our measly s/pm it's a freaking joke.....Big Pharma keeping lid on us....Here's the average analyst price target....GLTA

Oncolytics Biotech (NASDAQ:ONCY) Stock, Analyst Ratings, Price Targets, Forecasts

Oncolytics Biotech Inc has a consensus price target of $5 based on the ratings of 5 analysts. The high is $9 issued by JonesTrading on May 24, 2023. The low is $3 issued by Raymond James on April 4, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Raymond James on August 21, 2024, May 14, 2024, and April 4, 2024, respectively. With an average price target of $4.33 between HC Wainwright & Co., HC Wainwright & Co., and Raymond James, there's an implied 345.40% upside for Oncolytics Biotech Inc from these most-recent analyst ratings.